---
schema_version: "secwatch.filing_event.v1"
accession: "0001906324-22-000026"
form_type: "8-K"
ticker: "QDEL"
cik: "0001906324"
company_name: "QuidelOrtho Corp"
filed_at: "2022-10-12T23:59:59+00:00"
generated_at: "2026-06-23T04:10:34.579686+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# QuidelOrtho reports preliminary Q3 2022 revenue $782-785M; COVID revenue ~$171M

## Summary
- Total revenue expected $782M-$785M; non-COVID product revenue $611M-$614M.
- COVID-19 product revenue ~$171M, including unanticipated government order and strong retail demand.
- Strong performance in Transfusion Medicine and Sofia platform; Labs challenged by China and supply chain.
- Full Q3 2022 financial results to be reported on November 2, 2022.

## SEC filing metadata
- accession: 0001906324-22-000026
- form_type: 8-K
- ticker: QDEL
- cik: 0001906324
- company_name: QuidelOrtho Corp
- filed_at: 2022-10-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1906324/000190632422000026/0001906324-22-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1906324/000190632422000026/qdel-20221012.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001906324-22-000026
- JSON: https://secwatch.observer/filing/0001906324-22-000026.json
- Plain text: https://secwatch.observer/filing/0001906324-22-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.